125 results about "Polymorphanisini" patented technology

This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.

This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.

This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.

Disclosed in present invention are a novel cleavable linker compound as shown in formula (1) for a prodrug delivery system, and a pharmaceutically acceptable salt, solvate, polymorph or isomer thereof. Further disclosed are a prodrug compound as shown in formula (J) and formula (L) formed by covalently bonding an albumin or antibody to a camptothecin derivative by means of a novel linker compound, and a pharmaceutically acceptable salt, solvate, polymorph or isomer thereof. Further disclosed are a synthesis method for the compound, and a preparation method for the compound in an enzyme release prodrug system. Further disclosed are a use of the compound in preparation of an anti-tumor drug, and a use of the compound in preparation of an albumin-bound anti-tumor drug or antibody-drug conjugate. The present invention innovatively proposes a structure in which a trigger fragment in the compound is linked to the novel linker by means of p-hydroxyl or para-amino, an active drug is linked to the novel linker by means of the hydroxyl part of the active drug, and a modified fragment is linked to the novel linker by means of an amino group.

The present invention provides a compound as a PRMT5-MTA inhibitor, which is a compound represented by formula (I) or a pharmaceutically acceptable salt, isotope variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof. The present invention also provides a pharmaceutical composition comprising the compound and its use in the treatment of cancer.

This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.

The invention relates to a salt of a JAK kinase inhibitor and a crystal form of the salt, in particular to a polymorphic form of 2-{3-[3-amino-4-(7H-pyrrolo [2, 3-d] pyrimidine-4-yl)-1H-pyrazol-1-yl]-1-(isopropylsulfonyl) azetidin-3-yl} acetonitrile salt and a preparation method of the polymorphic form. The present application also relates to pharmaceutical compositions containing at least one polymorph and therapeutic or prophylactic uses of the polymorph and compositions.

The invention relates to a crystal form of a JAK kinase inhibitor, in particular to a polymorphic form of 2-{3-[3-amino-4-(7H-pyrrolo [2, 3-d] pyrimidine-4-yl)-1H-pyrazol-1-yl]-1-(isopropylsulfonyl) azetidin-3-yl} acetonitrile and a preparation method of the polymorphic form of the 2-{3-[3-amino-4-(7H-pyrrolo [2, 3-d] pyrimidine-4-yl)-1H-pyrazol-1-yl]-1-(isopropylsulfonyl) azetidin-3-yl} acetonitrile. The present application also relates to pharmaceutical compositions containing at least one polymorph and therapeutic or prophylactic uses of the polymorph and compositions.

The present disclosure relates to crystalline forms of N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidinium salts having high solubility. The disclosure also relates to use of said crystalline forms in medicine.

Provided are a class of PRMT5 inhibitors represented by formula (X), or pharmaceutically acceptable salts, isotope variants, tautomers, stereoisomers, prodrugs, polymorphs, hydrates or solvates thereof. The invention also provides a preparation method of the compound, a pharmaceutical composition containing the compound, and an application of the compound in prevention and treatment of cancers. # imgabs0 #

The invention provides a PARP1 inhibitor as shown in a formula (I), or pharmaceutically acceptable salts, isotope variants, tautomers, stereoisomers, prodrugs, polymorphs, hydrates or solvates of the PARP1 inhibitor. The invention also provides a preparation method of the compound, a pharmaceutical composition containing the compound, and an effect of the compound in prevention and treatment of cancers, ischemic diseases or neurodegenerative diseases. # imgabs0 #

The invention provides a polymorphic form of a compound (Z)-3-{3-[3, 5-bis (trifluoromethyl) phenyl]-1H-1, 2, 4-triazole-1-yl}-N '-(pyrazine-2-yl) acryloyl hydrazide shown as a formula (I), and the polymorphic form provided by the invention has better chemical stability, physical stability and lower hygroscopicity, is less influenced by heat, humidity and illumination, and is convenient to store and prepare. The invention further provides a preparation method of the polymorphic form of the compound (Z)-3-{3-[3, 5-bis (trifluoromethyl) phenyl]-1H-1, 2, 4-triazole-1-yl}-N'-(pyrazine-2-yl) acryloyl hydrazide.

The present invention is directed to the use of antiviral agents, in particular valomaciclovir stearate and its polymorph Form A, as well as H2G (omaciclovir) to treat multiple sclerosis in combination with other agents, as well as the use of these agents to treat diseases and conditions such as chronic mononucleosis, long COVID, chronic fatigue syndrome, fibromyalgia, Crohn's disease, ulcerative colitis, rheumatoid arthritis, systemic lupus erythematosus, Graves' disease, Alzheimer's disease, mesial temporal lobe seizures, Epstein-Barr-virus-linked autism, or an Epstein-Barr-virus-linked cancer.

Crystalline forms, including salts and polymorphs, of a compound useful in the treatment of tetracycline compound-responsive states are provided herein. The crystalline compounds are useful for the treatment or prevention of conditions and disorders such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds in general.

The present invention provides a polymorph of a CDK9 inhibitor and a preparation method for the polymorph and use thereof. Specifically, disclosed are 4-(((4-(5-chloro-2-(((1R,4r)-4-(((R)-1-methoxypropyl-2-yl)amino)cyclohexyl)amino)pyridine-4-yl)thiazole-2-yl)amino)methyl)tetrahydro-2H-pyrano-4-methylnitrile maleate or fumarate or polymorphs thereof and applications thereof. In addition, also disclosed are a pharmaceutical composition containing the substance and an application of the pharmaceutical composition.

The invention provides a PRMT5 inhibitor as shown in a formula (I), or pharmaceutically acceptable salts, isotope variants, tautomers, stereoisomers, prodrugs, polymorphs, hydrates or solvates of the PRMT5 inhibitor, or pharmaceutically acceptable salts, isotope variants, tautomers, stereoisomers, prodrugs, polymorphs, hydrates or solvates of the PRMT5 inhibitor. The invention also provides a preparation method of the compound, a pharmaceutical composition containing the compound, and an effect of the compound in prevention and treatment of cancers. # imgabs0 #

According to one or more embodiments, a zeolite beta material may be made by a method that may include adding a parent zeolite beta in a basic solution to form a basic zeolite beta suspension, adding water to the basic zeolite beta suspension to form a dilute basic zeolite beta suspension, hydrothermally treating the dilute basic zeolite beta suspension to form a hydrothermally treated mixture, and separating from the hydrothermally treated mixture a solid zeolite beta material consisting essentially of polymorph-A and polymorph-B. The molar ratio of polymorph-A to polymorph-B of the solid zeolite beta material is greater than molar ratio of polymorph-A to polymorph-B of the parent zeolite beta.

The present application relates to a kind of compound NMNH calcium salt, especially to a kind of reduced beta-nicotinamide mononucleotide calcium salt Polymorph and its preparation method, and they are used as pharmaceutical ingredients, health product ingredients, cosmetic ingredients or as food additive, and preparation containing these salts, belong to medicine, health product, cosmetic, food additive field.The specific, the present application describes NMNH calcium salt Polymorph, the crystal shows long-term sustained stability, significantly better than the stability of NMNH disodium salt, anti-hygroscopicity, more conducive to long-term storage, popularization and marketing.The NMNH calcium salt crystal preparation process is simple, easy to control, suitable for large-scale production.

Disclosed herein are salts and solid forms of MDMA, (R)-MDMA, (S)-MDMA, MDE, S-MDE, R-MDE, MDAI, MBDB, S-MBDB, R-MBDB, MEAI, and 5,6-Dimethoxy-2-aminoindane, including salts, solid forms of the compound and salts thereof, as well as polymorphs of solid forms. The solid forms disclosed herein may have improved properties, such as improved physical, chemical, and / or pharmacokinetic properties. Also disclosed are methods for making the salts and solid forms and methods for administering the same. The disclosed salt and solid forms of MDMA, (R)-MDMA, (S)-MDMA, MDE, S-MDE, R-MDE, MDAI, MBDB, S-MBDB, R-MBDB, MEAI, and 5,6-Dimethoxy-2-aminoindane may be useful for treating neurological disease and / or a psychiatric disorder in a subject.

The invention provides a targeting degradation chimera compound of targeting protein tyrosine phosphatase, and particularly relates to a compound shown as a formula (I), or pharmaceutically acceptable salt, isotope variant, tautomer, stereoisomer, prodrug, polymorphic form, hydrate or solvate thereof. The invention also provides a preparation method of the compound, a pharmaceutical composition containing the compound, and an effect of the compound in prevention and treatment of related diseases, such as hematological system tumors or solid tumor diseases. # imgabs0 #

Disclosed in the present invention are polymorphs of an IRAK-4 degrading agent. Specifically, the present invention provides a plurality of crystal forms of an IRAK-4 degrading agent represented by the following formula (I), salts thereof and crystal forms thereof, as well as a pharmaceutical composition thereof, the preparation therefor and the use thereof. The crystal forms provided by the present invention can be used for preparing drugs for treating and / or preventing IRAK4-mediated related diseases.

Novel compositions of N-desmethyl ruboxistaurin L-lactate salt and L-lactate salt polymorphs. The use of compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs to modulate GSK-3 signaling is disclosed, as is the use of compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs to inhibit protein kinase C. Methods are also disclosed of using compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs in the treatment of subjects having a neurological disease and / or psychiatric disorder, including Alzheimer's disease, bipolar disorder, depression, schizophrenia, Parkinson's disease, or neuroinflammation, as well as methods of using compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs in treating conditions associated with diabetes mellitus or its complications, or ischemia, inflammation, pulmonary hypertension, congestive heart failure, cardiovascular disease, dermatological disease, or cancer. In addition, compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs administered in combination with lithium or other treatments for bipolar disorder are also disclosed.

Provided herein are lipid compounds of Formulae (I) and (II), and pharmaceutically acceptable salts, co-crystals, tautomers, stereoisomers, solvates, hydrates, polymorphs, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive lipid compounds, compositions, or formulations for treating and / or preventing diseases (e.g., genetic disease, proliferative disease, hematological disease, neurological disease, painful condition, psychiatric disorder, metabolic disorder, long-term medical condition, inflammatory disease, autoinflammatory disease, liver disease, lung disease, spleen disease, familial amyloid neuropathy, cardiovascular disease, viral infection, infectious disease, fibrotic condition, or autoimmune disease) in a subject, methods for synthesizing the compounds described herein, and compounds described herein synthesized by the synthetic methods described herein. The compounds are effective carriers for the delivery of an agent such as a polynucleotide (e.g., RNA) to a tissue or cell in a subject (e.g., a liver, lung, or spleen tissue / cell).

The invention relates to the technical field of chemical synthesis of medicines, in particular to a pleuromutilin derivative, a preparation method thereof and an antibacterial active composition. The invention relates to a pleuromutilin derivative with a structure as shown in a formula I, or pharmaceutically and / or veterinary acceptable salt, a solvent compound, an optical isomer and a polymorphic compound of the pleuromutilin derivative. Formula I; wherein R1 is selected from one of a hydrogen atom and methyl; r2 is selected from one of a hydrogen atom and a methoxy group; and R3 is selected from one of cyclopropyl and p-fluorophenyl. According to the present invention, the quinolone drug is spliced to the pleuromutilin side chain to produce the new pleuromutilin derivative, and the obtained new compound can enhance the antibacterial activity, has significant antibacterial activity on Gram-positive bacteria and Gram-negative bacteria, and further has significant inhibition effect on MRSA and other drug-resistant bacteria so as to effectively broaden the antibacterial spectrum.

The present invention relates to novel polymorphic forms of Iptacopan hydrochloride and preparation thereof. The invention also relates to pharmaceutical composition comprising novel polymorphic forms of Iptacopan hydrochloride and their use in the treatment of paroxysmal nocturnal hemoglobinuria and proteinuria.

The invention relates to a polymorphic form of hydrobromide or hydrochloride of 5-(6-(4-(cyclopropylmethyl) piperazine-1-yl)-2-methylpyridine-3-yl)-N-((4, 6-dimethyl-2-oxo-1, 2-dihydropyridine-3-yl) methyl)-3-(N-ethylcyclopropanecarboxamide)-2-methylbenzamide, a pharmaceutical composition of the polymorphic form and application of the polymorphic form and the pharmaceutical composition of the hydrobromide or hydrochloride of the 5-(6-(4-(cyclopropylmethyl) piperazine-1-yl)-2-methylpyridine-3-yl)-N-(4, 6-dimethyl-2-oxo-1, 2-dihydropyridine-3-yl)-3-(N-ethylcyclopropanecarboxamide.